Reilly Financial Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Reilly Financial Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$239K	Hold	2,700	–	–	0.02%	190
2021 Q3	$209K	Hold	2,700	–	–	0.02%	192
2021 Q2	$225K	Hold	2,700	–	–	0.02%	197
2021 Q1	$204K	Hold	2,700	–	–	0.02%	192
2020 Q4	$237K	Hold	2,700	–	–	0.02%	174
2020 Q3	$205K	Hold	2,700	–	–	0.02%	176
2020 Q2	$333K	Hold	2,700	–	–	0.04%	147
2020 Q1	$228K	Hold	2,700	–	–	0.03%	159
2019 Q4	$228K	Hold	2,700	–	–	0.03%	175
2019 Q3	$182K	Hold	2,700	–	–	0.02%	192
2019 Q2	$231K	Hold	2,700	–	–	0.03%	171
2019 Q1	$240K	Hold	2,700	–	–	0.03%	161
2018 Q4	$230K	Hold	2,700	–	–	0.03%	162
2018 Q3	$262K	Hold	2,700	–	–	0.03%	158
2018 Q2	$254K	Buy	+2,700	New	+$236K	0.04%	154
2013 Q3	–	Sell	-50	Closed	-$3K	–	747
2013 Q2	$3K	Buy	+50	New	+$3.12K	﹤0.01%	694

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Reilly Financial Advisors's BMRN Position: Q4 2021 in Review

Reilly Financial Advisors held its BioMarin Pharmaceuticals (BMRN) position steady in Q4 2021 at 2,700 shares worth $239K. The position accounts for 0.02% of the portfolio, ranked #190.

Reilly Financial Advisors first reported a position in BMRN in Q2 2013 and has held it in 16 quarters since. The position peaked at $333K in Q2 2020. 557 funds tracked by Wall St. Rank hold BMRN as of Q4 2021.

Reilly Financial Advisors held 2,700 shares of BioMarin Pharmaceuticals worth $239K as of Q4 2021.
Reilly Financial Advisors left its BioMarin Pharmaceuticals share count unchanged in Q4 2021.
BioMarin Pharmaceuticals made up 0.02% of Reilly Financial Advisors's portfolio in Q4 2021, its #190 holding.
Reilly Financial Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 16 quarters since.
Reilly Financial Advisors's BioMarin Pharmaceuticals position peaked at $333K in Q2 2020.
557 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2021.

Based on Reilly Financial Advisors's 13F filing for Q4 2021, filed 25 Jan 2022.